SBIR/STTR Research Award
SBIR Phase I: High-Throughput AST Using Gradient-Based Microfluidic
Award amount
$305,000Program and phase
SBIR · Phase IAward year
2025Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- GIANT BioSystems Inc.
- Proposal award date
- 2025-02-26
- Contract end date
- 2026-02-28
- UEI
- FQZXTU2YRYK9
- Solicitation number
- NSF 24-579
- Topic code
- BM
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to create a rapid point-of-care antimicrobial susceptibility testing (AST) kit that can be run on the same day the sample is taken. This will help physicians to utilize the best antibiotic at the optimal dosage sooner, reducing the number of exposures for antimicrobial resistance (AMR). Such infections are responsible for more than 2.8 million infections and 35,000 deaths annually in the U.S. The integration of the proposed platform with mobile devices for result interpretation ensures that it can be widely deployed, including in resource-limited settings and during emergencies. This adoptability is crucial for promptly responding to future pandemics and ensuring that even remote or underserved areas have access to advanced diagnostic capabilities. This project will help to reduce the economic burden associated with AMR ($20 billion/year) and infectious diseases ($41 billion/year). Once commercialized, the proposed platform is expected to promote better antibiotic stewardship, reducing antibiotic release into the environment. Antibiotics in plants and the food chain pose risks to human and animal health, and contribute to the spread of resistant bacteria, making infections harder to treat and increasing outbreak risk. This Small Business Innovation Research (SBIR) Phase I project will develop a novel microfluidic platform for rapid and precise AST. Current methods, such as broth microdilution and Kirby-Bauer disk diffusion, are limited by long turnaround times of 3-5 days. This delay leads to a postponement in adjusting antibiotics. Even emerging rapid diagnostic systems, while quicker, still require >20 hours to provide results, resulting in >4 doses of broad-spectrum antibiotics before precision adjustments can be made. The proposed platform generates actionable results within 6-9 hours from time of sample, as opposed to the conventional 3-5 days, ident
Technology keywords
Not reported